Product Reports Resources Pricing Login Book a demo

Cellanome

Biotech & Life Sciences · Foster City, United States · Founded 2020

Cellanome is developing a unique multiomics platform to measure biology at an unprecedented resolution and scale MoreLess

Cellanome is a cutting-edge startup focused on revolutionizing the field of cell biology through its innovative automated platform. The company’s technology allows researchers to gain a deeper understanding of individual cell behaviors, interactions, and functions across a variety of conditions and parameters. This is achieved on a massive scale, enabling the study of numerous cells simultaneously.

The primary clients for Cellanome are researchers and professionals in the life sciences and medical fields. These clients benefit from the platform’s ability to perform live cell phenotypic and functional assays iteratively. This means that researchers can observe how cells react to different stimuli over time, providing a detailed view of cellular responses. Unlike traditional methods that often measure bulk responses, Cellanome’s platform highlights the unique reactions of individual cells, offering a more granular and precise analysis.

Operating in the biotechnology and life sciences market, Cellanome’s business model revolves around providing its platform as a service to research institutions, pharmaceutical companies, and biotech firms. The company generates revenue by offering subscriptions or licensing its technology, as well as through potential collaborations and partnerships with other entities in the field.

The platform is designed to integrate seamlessly into existing cell biology workflows, which means it can be easily adopted by labs without the need for significant changes to their current processes. This flexibility allows researchers to modify or create new live cell assays, making the platform a versatile tool in various experimental setups.

In summary, Cellanome is at the forefront of cell biology innovation, providing a powerful tool for researchers to explore cellular behaviors in unprecedented detail. The company’s focus on scalability and precision makes it a valuable asset in the life sciences and medical research communities.

Keywords: automated platform, cell biology, live cell assays, phenotypic analysis, functional assays, life sciences, medical research, biotechnology, cellular interactions, research innovation.

Company overview

Cellanome company information

The essential company record, classifications and operating signals in one place.

Status
Operational
Founded
2020
Headquarters
Foster City, United States
Employees
123
Open positions
15
Dealroom signal
94.1
client focusb2bsub industryBioTechnologysub industryHealth Platformbusiness modelManufacturingindustryHealthsectorBiotechnologysectorBiotech and PharmasectorHard TechsectorDT and LSsectorscience-based

Valuation & funding

Cellanome funding history

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Jan 2024 $150M $600M DCVC · 8VC
SERIES AOther financing Aug 2022 $30M $120M Undisclosed
SERIES AOther financing Dec 2021 $21M $84M Synetro Group
Showing 3 recorded eventsUnlock the complete deal history →

Growth signals

Cellanome website traffic

Latest recorded traffic for Cellanome is 4.5K monthly website visits, down 4.3% over the last three months. Cellanome's team grew 21.8% over the past year.

Latest monthly visits4.5K 3-month web change-4.3% 1-year team growth+21.8%
Monthly website visits45 observations · Oct 2022–Jul 2026
Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Cellanome compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Showing 8 of the closest matchesCompare every metric →

Talent graph

Cellanome's talent

Book a demo to see the people
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on Cellanome's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Series A 3 investors entered at this stage
Synetro Group
DCVC
8VC

Global footprint

Where Cellanome has talent and traffic

Workforce by country
4 countries with
team presence
🇺🇸 United States95.8%
🇸🇬 Singapore2.1%
🇬🇧 United Kingdom1.1%
🇰🇷 South Korea1.1%
4 countries shown

In the news

Latest news about Cellanome

Recent press, funding announcements, and product moves mentioning Cellanome — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Cellanome

An AI-synthesized read of the highest-engagement posts about Cellanome on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cellanome’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.